PARP1 and cancer: These findings highlight how PARP inhibitors effectively target HR-deficient cancer cells, not only by inhibiting enzymatic activity but also by physically trapping these proteins at DNA damage sites, hampering repair, and leading to increased cell death in cancers with homologous recombination deficiencies [58].